Clinical Trials Browser

NETWORK × Interventional × palbociclib × Clear all

NCT02630693 2026-04-13

Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer

Phase 2 Completed

180 enrolled 14 charts

Breast Neoplasms

NCT03820830 2026-04-09

POLAR

Phase 3 Active not recruiting

Breast Cancer Recurrent

NCT03297606 2026-03-27

CAPTUR

Phase 2 Recruiting

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT02905318 2026-03-09

Palbociclib in Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT03425838 2025-09-19

Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer

Phase 3 Active not recruiting

Breast Neoplasm Female

NCT04494958 2025-03-24

PALBOBIN

Phase 1/2 Completed

24 enrolled 10 charts

Triple Negative Breast Neoplasms

NCT03792256 2025-03-21

Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)

Phase 1 Completed

12 enrolled 24 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphoid, Recurrence, Leukemia, T-Cell, Lymphoma, T-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03644186 2024-12-13

TOUCH

Phase 2 Completed

147 enrolled 11 charts

Breast Neoplasms

NCT02536742 2024-02-26

PYTHIA

Phase 2 Completed

124 enrolled 10 charts

Breast Neoplasms, Neoplasm Metastasis

NCT03609047 2024-01-24

Appalaches

Phase 2 Active not recruiting

Breast Neoplasms

NCT03088059 2023-11-03

UPSTREAM

Phase 2 Unknown

Squamous Cell Carcinoma of Head and Neck

NCT03628066 2022-04-20

Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer

Phase 2 Completed

Breast Neoplasms

NCT02296801 2022-01-13

PALLET

Phase 2 Completed

307 enrolled 18 charts

Breast Neoplasms

NCT02785939 2021-05-27

Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

Phase 2/3 Completed

53 enrolled 15 charts

CCND1 Gene Amplification

NCT02255461 2021-03-02

Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors

Phase 1 Terminated

35 enrolled 28 charts

Astrocytoma, Glioblastoma, Medulloblastoma, Oligodendroglioma, Choroid Plexus Neoplasms, Neoplasms, Neuroepithelial